Introduction
============

Prostate cancer (PCa) is the second most common cancer in men, and the fourth most common cancer worldwide. More than one million men worldwide were diagnosed with PCa in 2012 ^[@ref-1]^. The incidence of local-regional PCa has increased since the introduction of prostate specific antigen (PSA). This circumstance reduces the incidence of metastatic PCa ^[@ref-2]^. PCa patient treated at early stages have a good prognosis with 5-year overall survival (OS) reaching 99%. In contrast, metastatic PCa patients generally experience a poor outcome. Several published studies showed a wide difference of survival, with median OS from two to five years ^[@ref-3]--\ [@ref-5]^. Androgen deprivation therapy (ADT) becomes the standard treatment of patients with advanced PCa ^[@ref-6],\ [@ref-7]^, and with the first use reported by Huggins and Hodges in 1941 ^[@ref-8]^.

In clinical practice, PSA is the most common diagnostic procedure to evaluate the disease and to predict the survival. PSA kinetics such as nadir PSA level, time to reach nadir (TTN), or specific PSA value after initiation of ADT might became a predictor of survival in several retrospective and clinical trial studies ^[@ref-5],\ [@ref-9]--\ [@ref-11]^. Some limitations were shown in the previous report of investigation for PSA kinetic to survival. They included patients with heterogeneous backgrounds (such as metastatic disease prior to surgical or radiation therapy), and the sample size was small. Therefore, we performed a systematic review and meta-analysis to evaluate the pooled effect of PSA kinetics of patient treated with hormonal therapy related to survival from several published studies.

Methods
=======

Eligibility criteria
--------------------

The systematic review was performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines ^[@ref-12]^. All studies in English were included. Retrospective cohorts, prospective cohort, randomized clinical trial (RCT), were eligible for inclusion for this review. The inclusion criteria were that (i) the participant of the study had metastatic PCa; (ii) patients were treated with ADT either using orchiectomy or luteinizing hormone-releasing hormone (LHRH) agonist with or without anti-androgen (AA); (iii) the studies outcome were either progresion free survival (PFS), overall survival (OS) or cancer specific survival (CSS); (iv) the studies had to analyze PSA kinetics (intial PSA prior to initiation of ADT, PSA nadir, and time to reach nadir (TTN) PSA). Studies analyzed in meta-analysis had to use adjusted analysis of prognostic factors, such as multivariate Cox regression, to overcome the confounding factors. Studies that analyzed patient with castration resistant PCa (CRPC) and non-metastatic disease were excluded.

Search strategy
---------------

Electronic searched were performed in three databases: MEDLINE, Science Direct, and Cochrane Library from 1950 to 2016. This literature searching was conducted in March 2017. Gray literature and conference abstract, especially from urology oncology conference, were also searched. References list from included article were reviewed. We used the following search strategy: (prostate cancer OR adenocarcinoma prostate), (survival OR prognosis OR prognostic), (metastasis OR metastases OR metastatic), (PSA OR "Prostate Specific Antigen" OR nadir OR "initial PSA" OR kinetic). Two researchers (A.A and A.R.A.H) were indecently assessing the title and abstract of the paper. They agreed the studies included in the meta-analysis. Disagreement between the two review authors on the selection of studies was resolved by discussion with third authors (C.A.M) as a senior investigator. We used [EndNote](http://endnote.com/product-details) X6 for screening of duplicated studies.

Data extraction and quality assessment
--------------------------------------

A data extraction table was created to extract data from each article. The data of study design, patient\'s characteristics, method of ADT, duration of follow up, outcomes of survival, and significant prognostic factors of PSA kinetics were collected from all included studies. For the observational studies, the quality of study was assessed using Newcastle-Ottawa Scale (NOS). There were three major components of this scale namely the selection of the group of the study, comparability, and assessment of the outcome. The quality of study assessed with number of stars based on NOS. A maximum 7 stars could be scored; 6 or 7 stars considered as high quality study, 4 -- 5 stars corresponded with intermediate quality, and 0 -- 3 stars showed low quality ^[@ref-13]^.

Synthesis of results
--------------------

Meta-analysis was applied on studies with prognostic factor with similar outcome definition. I ^2^ test was conducted in order to evaluate the heterogeneity, whilst for \>30% a random effects model was applied, or otherwise, fixed effects model was done. Confounding in the individual studies was estimated using Hazard Ratio (HR) adjusted estimation, thus generic inverse variance method was used. We only combined data to estimate pooled effect of categorical parameters due to feasibility of statistical analysis. Studies that evaluated parameters but could not synthesize to meta-analysis were describe quantitatively. Meta-analysis was performed using [Review Manager](http://community.cochrane.org/tools/review-production-tools/revman-5) 5.2 from Cochrane Collaboration. A p-value \< 0.05 was considered statistically significant.

Results
=======

We found 873 citations throughout database searching. No additional records identified through searching from reference list of included studies. Seventeen studies were found to be consistent to the inclusion criteria of the study, but seven studies could not be evaluated the in meta-analysis ( [Figure 1](#f1){ref-type="fig"}). Miyamoto *et al.* ^[@ref-14]^ did not published the hazard ratio, and put the cumulative survival rate as the outcome. Six other studies used numerical parameters of PSA kinetics that cannot combine in the forest plot ^[@ref-9],\ [@ref-15]--\ [@ref-19]^. All of those studies were considered in qualitative synthesis. The characteristic of study is present in [Table 1](#T1){ref-type="table"}. Based on NOS, the quality of study included was good ( [Table 2](#T2){ref-type="table"}).

![Flowchart showing the searching strategy of the studies.](f1000research-7-15244-g0000){#f1}

###### Characteristic of included studies.

  --------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                       Total\         Androgen Deprivation\         Follow - up time    Survival outcome               Significance Prognostic\
                              patient        Therapy                                                                          Factor
  --------------------------- -------------- ----------------------------- ------------------- ------------------------------ ----------------------------
  Bello 2017 ^[@ref-25]^      M1 = 79        •   Orchiectomy\              NM                  Median OS was 40.3 months      •   NSAID use\
                                             •   LHRH agonist                                                                 •   PSA nadir

  Choueiri 2009 ^[@ref-5]^    M1 = 179       •   LHRH agonist with or\     Median follow up\   Median OS was 84 months        •   GS\
                                                 without AA\               48 months                                          •   TTN\
                                             •   Orchiectomy                                                                  •   PSA Nadir

  Glass 2003 ^[@ref-9]^       M1 = 1,076     Bilateral orchiectomy with\   NM                  Median OS was 32 months        •   Initial PSA\
                                             or without AA (flutamide)                                                        •   Presence appendicular\
                                                                                                                                  bone disease\
                                                                                                                              •   GS\
                                                                                                                              •   Presence of bone pain\
                                                                                                                              •   PS

  Hong 2012 ^[@ref-10]^       M1 = 131       CAB using LHRH agonist\       Median follow up\   Median CSS\                    •   PSA nadir\
                                             plus AA                       30 months           •   PSA nadir \< 2 ng/ml\      •   TTN
                                                                                                   was 91.7 months\           
                                                                                               •   PSA nadir ≥ 2 ng/ml 49.8   

  Hussain 2006 ^[@ref-11]^    M1 = 1,345     CAB using LHRH agonist\       Median follow up\   Median OS of PSA after\        •   PSA after 7 months\
                                             (gosereline) plus AA\         was 38.0 months     7 months ADT\                      of ADT\
                                             (bicalutamide)                                    •   ≤ 0.2 ng/ml was\           •   ECOG\
                                                                                                   75 months\                 •   Presence of bone pain\
                                                                                               •   0.2 \< PSA ≤ 0.2 ng/ml\    •   GS
                                                                                                   was 44 months\             
                                                                                               •   PSA \> 4.0 ng/ml was\      
                                                                                                   13 months                  

  Kadono Y, 2015 ^[@ref-4]^   M1a = 224,\    •   LHRH agonist with or\     Mean follow up\     The 5-year OS was\             •   GS\
                              M1b = 4386,\       without AA\               3.3 years           •   57.5% in M1a\              •   PSA\
                              M1c =278       •   Orchiectomy                                   •   54.0% in M1b\              •   Age
                                                                                               •   40.0% in M1c               

  Kim KH, 2015 ^[@ref-18]^    M1 = 398       •   CAB (LHRH agonist\        Median follow up\   Median CSS was 65 months       •   GS\
                                                 plus AA)                  44 months                                          •   PSA nadir\
                                                                                                                              •   TTN\
                                                                                                                              •   PSA Half Life\
                                                                                                                              •   N1

  Kimura, 2014 ^[@ref-24]^    M1 = 3006      •   Type of ADT was not\      Median followed\    The 5-years OS\                •   GS\
                                                 clear                     up in young,\       •   Young age was 26.6%\       •   Concomitant bone and\
                                                                           middle and\         •   Middle age was 59.7%\          visceral metastasis\
                                                                           elderly group\      •   Elderly age was 55.3%      •   Age\
                                                                           was 25.5, 35.3\                                    •   Clinical T
                                                                           and 38.5 months                                    

  Koo, 2014 ^[@ref-17]^       M1b = 248      •   Type of ADT was not\      Median follow up\   Median CSS in PSA nadir\       •   PSA nadir\
                                                 clear                     39.3 months         •   \< 0.2 ng/ml was\          •   ALP\
                                                                                                   70 months\                 •   ECOG
                                                                                               •   ≥ 0.2 ng/ml was\           
                                                                                                   50 months                  

  Kwak 2002 ^[@ref-23]^       M1 = 145       •   LHRH agonist with or\     Median follow up\   Median survival of patients\   •   Nadir PSA
                                                 without AA\               39 months           with Nadir PSA (months)\       
                                             •   Orchiectomy                                   •   \< 0.2, = 53\              
                                                                                               •   0.2 to 1.0 = 42\           
                                                                                               •   1.1 to 10 = 24\            
                                                                                               •   \>10.1 = 15                

  Miller 1992 ^[@ref-25]^     M1 = 48\       •   Orchiectomy\              Median follow up\   Median PFS 19 months           •   Nadir PSA
                              patients       •   LHRH agonist\             42 months                                          
                                             •   Diethylatibestrol                                                            

  Miyamoto ^[@ref-14]^        M1 -- 94       •   LHRH agonist with AA      Median follow up\   5-yr OS rate 62.5%             •   PSA\
                                                                           38.8 months                                        •   Gleason Grade

  Nayyar 2010 ^[@ref-16]^     M1 = 412       •   Surgical castration\      Median follow up\   Median OS 5.7 years            •   GS\
                                             •   Medical castration\       55 months                                          •   PSA doubling time
                                             •   Antiandrogen                                                                 

  Park, 2009 ^[@ref-15]^      M1 = 131       •   LHRH agonist with or\     Median follow up\   Median CSS\                    •   High Nadir PSA\
                                                 without AA\               was 53.0 months     •   Short PSA doubling\        •   Short PSA half time\
                                             •   Orchiectomy                                       time was 35 months\        •   Short PSA doubling\
                                                                                               •   Long PSA doubling\             time after nadir
                                                                                                   time 95 months             

  Sasaki 2011 ^[@ref-22]^     M1 = 412       •   Bilateral orchiectomy\    NM                  Median OS 5.7 years            •   PSA half time\
                                             •   LHRH agonist                                                                 •   PSA doubling time\
                                                                                                                              •   GS

  Teoh 2017 ^[@ref-21]^       M1b = 419      •   LHRH agonist\             Median follow up\   Median OS was 28 months        •   PSA nadir ≥ 2 ng/ml\
                                             •   Bilateral orchiectomy     was 48 months                                      •   TTN \< 9.09 months

  Tomiokoa 2014 ^[@ref-20]^   M1 = 236       •   LHRH agonist\             Median follow up\   The 5-years OS was 63%         •   Nadir PSA ≥ 0.2 ng/ml\
                                             •   surgical castration\      47 months                                          •   TTN \< 6 month
                                             •   AA monotherapy\                                                              
                                             •   CAB                                                                          
  --------------------------------------------------------------------------------------------------------------------------------------------------------

ADT = androgen deprivation therapy; LHRH = luteinizing hormone releasing hormone; AA = anti androgen; CAB = combined anti androgen; PSA = prostate specific antigen; OS = overall survival; GS = Gleason score; TTN = time to nadir; NM = not mentioned; NSAID = non-steroidal anti inflammatory drug; ECOG PS = Eastern Cooperative Oncology Group Performance Status; PS = Performance Status; ALP = alkaline phosphatase; N1= regional nodal metastasis

###### Methodological quality of the study based on NOS Scale.

  ----------------------------------------------------------------------------------------------------------------------------
  Study                      Selection\       Comparability\   Outcome\       Total\                                       
                             (Max \*\*\*\*)   (Max \*\*)       (Max \*\*\*)   Score                                        
  -------------------------- ---------------- ---------------- -------------- -------- ------ ---- ----------- ----------- ---
  Bello 2017 ^[@ref-25]^     \*               \*               \*             \*       \*\*   \*   Not clear   Not clear   7

  Choueiri 2009 ^[@ref-5]^   \*               \*               \*             \*       \*     \*   \*          \*          9

  Glass 2003 ^[@ref-9]^      \*               \*               \*             \*       \*\*   \*   Not clear   Not clear   7

  Hong 2012 ^[@ref-10]^      \*               \*               \*             \*       \*\*   \*   \*          \*          9

  Hussain 2006 ^[@ref-11]^   \*               \*               \*             \*       \*\*   \*   \*          \*          9

  Kadono 2015 ^[@ref-4]^     \*               \*               \*             \*       \*\*   \*   \*          \*          9

  Kim 2015 ^[@ref-18]^       \*               \*               \*             \*       \*\*   \*   \*          \*          9

  Kimura 2014 ^[@ref-24]^    \*               \*               \*             \*       \*     \*   \*          \*          8

  Koo 2014 ^[@ref-17]^       \*               \*               \*             \*       \*\*   \*   \*          \*          9

  Kwak 2002                  \*               \*               \*             \*       \*\*   \*   \*          \*          9

  Miller 1992 ^[@ref-19]^    \*               \*               \*             \*       \*     \*   \*          \*          8

  Miyamoto\                  \*               \*               \*             \*       \*\*   \*   \*          \*          9
  2012 ^[@ref-14]^                                                                                                         

  Nayyar 2010                \*               \*               \*             \*       \*\*   \*   \*          \*          9

  Park 2009 ^[@ref-15]^      \*               \*               \*             \*       \*\*   \*   \*          \*          9

  Sasaki 2011 ^[@ref-22]^    \*               \*               \*             \*       \*\*   \*   \-          \*          7

  Teoh 2017 ^[@ref-21]^      \*               \*               \*             \*       \*\*   \*   \*          \*          9

  Tomioka 2014 ^[@ref-20]^   \*               \*               \*             \*       \*\*   \*   \*          \*          9
  ----------------------------------------------------------------------------------------------------------------------------

Evaluation of PSA kinetics
--------------------------

***Initial PSA***. Initial PSA before ADT treatment was evaluated in twelve studies ^[@ref-4],\ [@ref-9]--\ [@ref-11],\ [@ref-16],\ [@ref-17],\ [@ref-19]--\ [@ref-25]^. However, we only put four studies in PFS outcome and four studies in CSS/OS outcome because the studies analyzed initial PSA as a categorical parameter. No significant association between initial PSA and PFS was found, and the studies were homogenous (I ^2^=0%). In addition, there was no association between initial PSA and CSS/OS ( [Figure 2](#f2){ref-type="fig"}). In qualitative analysis, four studies analyzed the association between initial PSA and PFS. All of the studies did not find significant results for PSA and PFS ^[@ref-16],\ [@ref-17],\ [@ref-19],\ [@ref-25]^. The result was the same when we analyzed the studies for OS/CSS outcome ^[@ref-9],\ [@ref-11],\ [@ref-16]^.

![Forest plot of association between initial PSA and: **A**) Progression Free Survival Outcome; **B**) Cancer Specific Survival/Overall Survival.](f1000research-7-15244-g0001){#f2}

***PSA Nadir***. Six studies analyzed the effect of PSA nadir to influence survival using 0.2 ng/ml as a cut-off point ^[@ref-5],\ [@ref-10],\ [@ref-11],\ [@ref-20],\ [@ref-22],\ [@ref-23]^. Four studies analyzed the PSA nadir as a continuous variable ^[@ref-15],\ [@ref-17]--\ [@ref-19]^. Teoh *et al.* used cut-off point 2 ng/ml as a PSA nadir that influence the survival ^[@ref-21]^. Bello *et al.* analysed nadir using 4 ng/ml as a threshold ^[@ref-25]^. Meta-analysis of the studies found an association of reduced PFS of patient with high PSA nadir (HR 2.22; 95% CI 1.82 to 2.70). The studies appear homogenous in the forest plot. In addition, high PSA nadir had a negative impact on the OS/CSS outcome with HR 3.31 (95% CI 2.01--5.43) ( [Figure 3](#f3){ref-type="fig"}). In the studies using continuous measurement of PSA nadir, three studies found significant association of nadir PSA and survival ^[@ref-15],\ [@ref-18],\ [@ref-19]^. However, studies by Koo *et al.* found no significant result ^[@ref-17]^. Miyamoto *et al.* found the PSA nadir after first line hormonal therapy influenced survival ^[@ref-14]^.

![Forest plot of association between PSA nadir and: **A**) Progression Free Survival Outcome; **B**) Cancer Specific Survival/Overall Survival.](f1000research-7-15244-g0002){#f3}

***Time to Nadir (TTN)***. A total of seven studies analyzed the relationship between TTN and survival ^[@ref-5],\ [@ref-10],\ [@ref-16]--\ [@ref-18],\ [@ref-20],\ [@ref-21]^. Of the seven studies, two studies used 8 months ^[@ref-5],\ [@ref-10]^, one study used 9 months ^[@ref-26]^, and one study used 12 months ^[@ref-20]^ as a cut-off. Three studies analyzed TTN as a continuous variable ^[@ref-16]--\ [@ref-18]^. Meta-analysis was performed with showing a shorter TTN correlated with poor survival for both PFS (HR 2.41; 95% CI 1.19 -- 4.86) or CSS/OS (HR 1.80; 95%CI 1.42 -- 2.30) ( [Figure 4](#f4){ref-type="fig"}). Studies using continuous variable of TTN showed a significant negative effect from shorter TTN on survival.

![Forest plot of association between TTN and: **A**) Progression Free Survival Outcome; **B**) Cancer Specific Survival/Overall Survival.](f1000research-7-15244-g0003){#f4}
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Discussion
==========

Nowadays, clinicians have use PSA not only for screening for PCa, but also for follow up of patients after the treatment. The PSA indicates PCa condition following radical treatment in localized disease, and hormonal treatment in metastatic condition. PSA has a prognostic value, and now has been widen to several parameters such as PSA nadir, TTN, PSA doubling time, and PSA response after the treatment. There is controversy among previous study about the utilization of the PSA kinetic after hormonal treatment for predicting the progression to CRPC and survival.

The meta-analysis performed in this study did not find an association between survival and high initial PSA. Significant heterogeneity was observed due to scattered cut off points of high initial PSA amongst the studies included. Several studies found significant association of initial PSA and survival in univariate analysis, but lost significant after multivariate analysis. This condition showed us the aggressiveness of the cancer has not reflected by PSA alone, and other measures such as Gleason score, PSA nadir, and PSA decline may need to be considered ^[@ref-10],\ [@ref-15]^. This finding was different in localized diseases. High initial PSA reflects disease burden and was found to be correlated with the pathological stage, Gleason score, and the risk of metastasis. The National Comprehensive Cancer Network (NCCN) guideline stratified the risk of localized disease based on PSA and that influences the treatment choice ^[@ref-27]^.

The significant findings of this study showed that lower PSA nadir was associated with good prognosis after ADT treatment. However, due to the variety of PSA nadir threshold, we could not conclude the best optimal threshold of PSA nadir. Most of the papers in this meta-analysis were using below 0.2 ng/ml PSA nadir. Morote *et al.* analyzed 185 patients with metastatic prostate cancer and they found nadir PSA above 0.2 ng/ml was associated with 20 times likelihood progression to CRPC ^[@ref-28]^. Moreover, Stewart *et al.* analyzed patient who received ADT due to biochemical recurrence after radical prostatectomy or radiation therapy, and they suggested PSA nadir above 0.2 ng/ml was associated with significant progression and mortality ^[@ref-29]^. Keizman *et al.* used a different cut off for PSA nadir. They were using below 0.1 ng/ml because they found 4 times increased likelihood of biochemical or clinical progression in patients treated with intermittent ADT due to relapse after radical treatment ^[@ref-30]^.

Our findings found an association between longer time to get nadir PSA and survival. Longer time to nadir was associated with good prognosis. A study by Chung *et al.* found longer time to achieve nadir was a good prognosis for postoperative or post-radiation failure patients receiving ADT ^[@ref-31]^. Possible mechanisms of longer time to nadir associated with a good prognosis was associated with differentiation of PCa cells. Rapid reduction of hormone sensitive cancer cells may induce an environment for the development of hormone resistant PCa cells. In addition, PCa cells that have potential to differentiate into castration resistant cell show a rapid reduction of PSA due to ablation of the androgen receptor. Thus, rapid reduction of PSA is associated to development of CRPC and has a poor prognosis ^[@ref-32]^. This phenomenon is opposite to organ confined PCa receiving radical prostatectomy. In this setting, rapid decline of PSA result is associated with a better prognosis ^[@ref-33]^.

This study has some methodological limitations. We did not analyze the method of administration of ADT due to heterogeneity of ADT administration and that might be influenced survival. Some of the PSA kinetics evaluated in this meta-analysis had significant high heterogeneity. The strengths of this study include (i) a high quality of study based on NOS scale; (ii) meta-analysis just included study with multivariate analysis (iii) several parameters that were associated with the survival were found in this study and might be evaluated in the future research.

Conclusion
==========

In this study, the intial PSA before administering ADT did not influence the PFS or OS/CSS. Higher PSA nadir during ADT treatment was associated with shortened progression time and survival. A longer time to nadir is a good prognosis of progression and survival of mPCA treated with ADT.
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**Dataset 1.** Quality assessment (based on NOS), hazard ratio, and standard error of studies included in initial PSA parameter. For quality assessment a maximum 7 stars could be scored; 6 or 7 stars considered as high quality study, 4 -- 5 stars corresponded with intermediate quality, and 0 -- 3 stars showed low quality. [10.5256/f1000research.14026.d195553](http://dx.doi.org/10.5256/f1000research.14026.d195553) ^[@ref-34]^

**Dataset 2**. Quality assessment (based on NOS), hazard ratio, and standard error of studies included in PSA nadir parameter. For quality assessment a maximum 7 stars could be scored; 6 or 7 stars considered as high quality study, 4 -- 5 stars corresponded with intermediate quality, and 0 -- 3 stars showed low quality. [10.5256/f1000research.14026.d195573](http://dx.doi.org/10.5256/f1000research.14026.d195573) ^[@ref-35]^

**Dataset 3**. Quality assessment (based on NOS), hazard ratio, and standard error of studies included in time to nadir parameter. For quality assessment a maximum 7 stars could be scored; 6 or 7 stars considered as high quality study, 4 -- 5 stars corresponded with intermediate quality, and 0 -- 3 stars showed low quality. [10.5256/f1000research.14026.d195577](http://dx.doi.org/10.5256/f1000research.14026.d195577) ^[@ref-36]^
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This article demonstrated the importance of PSA kinetic in prognosis of prostate cancer that received ADT.

1\. One of important PSA kinetic is PSA doubling time; this should be in the analysis if possible.

2\. The sentence in discussion session" This condition showed us the aggressiveness of the cancer has not reflected by PSA alone, and other measures such as Gleason score, PSA nadir, and PSA decline may need to be considered." As we know that Gleason score as the aggressiveness of cancer is one of very important factors in all CSS and OS, this should be more detail written in text.

3\. Volume of tumor is very important in combination upfront of chemotherapy /Noval hormonal therapy, this should be added in text that may be related with high initial PSA level.
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This article seeks to show correlation between PSA kinetics (initial PSA, PSA nadir, time to nadir) and outcome in patients with metastatic prostate cancer (mPCa) receiving initial treatment with androgen-deprivation therapy (ADT) in terms of survival (PFS, CSS, OS). Seventeen studies were included based on the inclusion and exclusion criteria. The results showed that survival was correlated with PSA nadir and time to nadir (TTN) but not with initial PSA level. Low PSA nadir and long TTN are associated with improved survival. However, due to variation across the studies, no conclusion can be made on the cut-off level of PSA nadir and TTN.

Overall it was well written. But some areas require review / modification: Methods The inclusion criteria (ii) states that patients were treated with ADT (orchiectomy / LHRH agonists with or without anti-androgen). However, based on Table 1 there are two studies that used anti-androgen monotherapy ^[@rep-ref-33670-1]^ ^-^ ^[@rep-ref-33670-2]^. Anti-androgen monotherapy is not included in the criteria.The studies seem to be rather heterogeneous in terms of the outcome measured and the definition of PSA kinetics. Table 1 summarized the studies nicely. But there are inconsistencies in the information given on individual studies in survival outcome column. I guess these are the outcome as reported by the studies. But for the purpose of this review, it would be useful to include on how the parameters studied in this review were defined / analysed in the individual studies i.e. the measurement of PSA kinetics and their definitions / cut-off. Results There is variation in the survival outcome parameter reported by the studies - some reported median survival while others reported survival at various time-points e.g. 5-year OS. CSS has been combined with OS (Figures 2,3 & 4). I think this is not ideal since they do not refer to the same outcome but I assume this was done because the number of studies would be too small if they were to be assessed and reported separately.Need to check on the validity of the above with statistician.Discussion In para 4, it was stated that \'Our findings found an association between longer time to get nadir PSA and survival'. I suggest some comments are made on the reasonable time-points to categorise between short and long TTN to guide readers.Since there are quite a variation across the studies in the types of ADT used (ADT alone, ADT + anti-androgen, anti-androgen alone), good to add some comments on this and what data we may have on possible impact on PSA kinetics and survival.In the current era where chemohormonal and ADT in combination with abiraterone acetate have become the new standard of care for metastatic castrate sensitive prostate cancer, good to add some comments on this as we may not know how much the PSA kinetics may be prognostic of survival outcome in patients who are treated with these approaches instead of ADT alone and how the outcome of this review may or may not be applicable to these patients. There are some errors in grammar / sentence structure / choice of words throughout the manuscript that should be reviewed and corrected. Some examples: Page 3 Introduction para 2: "In clinical practice....... PSA kinetics....might became a predictor of survival in several retrospective and clinical trial studies.", should be written as "In clinical practice....... PSA kinetics....have been shown to be predictors of survival in several retrospective and prospective clinical studies."Page 3 Methods under Search Strategy section: "Two researchers...were indecently assessing the title and abstract of the paper. They agreed the studies included in the meta-analysis." This could perhaps be written as "The titles and abstracts of the papers were extensively assessed by two researchers. The studies for meta-analysis were selected based on the inclusion and exclusion criteria.".Page 9 Discussion para 2: "Several studies found....., but lost significant after multivariate analysis.", can be written as "Several studies found....., but the association was not significant after multivariate analysis." or "Several studies found....., but lost its significance after multivariate analysis.",Some figures were shown on page 7 - Datasets 1-3, but they are not explained / referred to in the text. These seem to be redundant. They are already documented on page 9 after the Conclusion.
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In this meta-analysis, the authors analyzed the prognostic value of PSA kinetics in patients with mPCa. They concluded that higher PSA nadir during ADT treatment was associated with shortened progression time and survival. Although the topic was not new, the review has archival value. I have several concerns about the MS and I suggest major revision.  In the aim of the abstract, "hormonal therapy" should be replaced by "ADT" with regard to the homogeneity of the terms.In the introduction part, an explicit statement of the participants, interventions, comparisons, outcomes, and study design (PICOS) is essential.The ADT methods and cut-off point about the PSA indicators varied from different studies, which can result in potential bias. This limitation should be focused and comprehensively discussed.There were several grammar mistakes in the MS. For example, In the table 1. "Significance Prognostic Factor" should be "Significant Prognostic Factor".

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

[^1]: No competing interests were disclosed.
